CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 170.76 Billion KRW | 3.62% |
| 2022 | 164.79 Billion KRW | 20.24% |
| 2021 | 137.04 Billion KRW | 19.47% |
| 2020 | 114.71 Billion KRW | 53.19% |
| 2019 | 74.88 Billion KRW | 103.17% |
| 2018 | 36.85 Billion KRW | -1.55% |
| 2017 | 37.43 Billion KRW | -18.17% |
| 2016 | 45.74 Billion KRW | 5.73% |
| 2015 | 43.26 Billion KRW | 0.1% |
| 2014 | 43.22 Billion KRW | -16.27% |
| 2013 | 51.62 Billion KRW | -15.75% |
| 2012 | 61.27 Billion KRW | -22.72% |
| 2011 | 79.28 Billion KRW | 88.21% |
| 2010 | 42.12 Billion KRW | -10.72% |
| 2009 | 47.18 Billion KRW | 3.25% |
| 2008 | 45.69 Billion KRW | 4.04% |
| 2007 | 43.92 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 167.56 Billion KRW | -3.04% |
| 2024 Q1 | 172.81 Billion KRW | 1.2% |
| 2023 Q2 | 165.7 Billion KRW | -0.09% |
| 2023 Q3 | 188.59 Billion KRW | 13.81% |
| 2023 Q4 | 170.76 Billion KRW | -9.45% |
| 2023 FY | 170.76 Billion KRW | 3.62% |
| 2023 Q1 | 165.86 Billion KRW | 0.65% |
| 2022 Q3 | 157.92 Billion KRW | 10.86% |
| 2022 Q2 | 142.45 Billion KRW | 4.33% |
| 2022 FY | 164.79 Billion KRW | 20.24% |
| 2022 Q1 | 136.54 Billion KRW | -0.37% |
| 2022 Q4 | 164.79 Billion KRW | 4.35% |
| 2021 FY | 137.04 Billion KRW | 19.47% |
| 2021 Q2 | 128.53 Billion KRW | -0.66% |
| 2021 Q1 | 129.38 Billion KRW | 12.79% |
| 2021 Q4 | 137.04 Billion KRW | 2.47% |
| 2021 Q3 | 133.74 Billion KRW | 4.05% |
| 2020 Q4 | 114.71 Billion KRW | -2.03% |
| 2020 Q1 | 91.36 Billion KRW | 22.01% |
| 2020 Q2 | 103.84 Billion KRW | 13.66% |
| 2020 Q3 | 117.09 Billion KRW | 12.75% |
| 2020 FY | 114.71 Billion KRW | 53.19% |
| 2019 Q4 | 74.88 Billion KRW | 38.94% |
| 2019 FY | 74.88 Billion KRW | 103.17% |
| 2019 Q1 | 50.96 Billion KRW | 38.27% |
| 2019 Q2 | 56.17 Billion KRW | 10.22% |
| 2019 Q3 | 53.89 Billion KRW | -4.05% |
| 2018 FY | 36.85 Billion KRW | -1.55% |
| 2018 Q4 | 36.85 Billion KRW | -14.38% |
| 2018 Q3 | 43.04 Billion KRW | 3.96% |
| 2018 Q2 | 41.4 Billion KRW | -1.58% |
| 2018 Q1 | 42.07 Billion KRW | 12.38% |
| 2017 Q4 | 37.43 Billion KRW | -11.35% |
| 2017 FY | 37.43 Billion KRW | -18.17% |
| 2017 Q3 | 42.23 Billion KRW | -7.67% |
| 2017 Q2 | 45.74 Billion KRW | -0.88% |
| 2017 Q1 | 46.14 Billion KRW | 0.87% |
| 2016 Q2 | 43.54 Billion KRW | -12.32% |
| 2016 Q3 | 43.11 Billion KRW | -0.99% |
| 2016 FY | 45.74 Billion KRW | 5.73% |
| 2016 Q4 | 45.74 Billion KRW | 6.11% |
| 2016 Q1 | 49.66 Billion KRW | 14.78% |
| 2015 Q1 | 42.21 Billion KRW | -2.34% |
| 2015 Q3 | 46.59 Billion KRW | -9.89% |
| 2015 Q2 | 51.7 Billion KRW | 22.5% |
| 2015 Q4 | 43.26 Billion KRW | -7.14% |
| 2015 FY | 43.26 Billion KRW | 0.1% |
| 2014 FY | 43.22 Billion KRW | -16.27% |
| 2014 Q4 | 43.22 Billion KRW | 1.56% |
| 2014 Q3 | 42.56 Billion KRW | -8.47% |
| 2014 Q1 | 53.52 Billion KRW | 3.68% |
| 2014 Q2 | 46.49 Billion KRW | -13.13% |
| 2013 Q4 | 51.62 Billion KRW | 1.05% |
| 2013 FY | 51.62 Billion KRW | -15.75% |
| 2013 Q1 | 61.53 Billion KRW | 0.42% |
| 2013 Q2 | 53.93 Billion KRW | -12.35% |
| 2013 Q3 | 51.08 Billion KRW | -5.28% |
| 2012 Q2 | 59.18 Billion KRW | -10.77% |
| 2012 Q1 | 66.33 Billion KRW | -16.34% |
| 2012 Q3 | 65.42 Billion KRW | 10.53% |
| 2012 FY | 61.27 Billion KRW | -22.72% |
| 2012 Q4 | 61.27 Billion KRW | -6.34% |
| 2011 FY | 79.28 Billion KRW | 88.21% |
| 2011 Q4 | 79.28 Billion KRW | 1.87% |
| 2011 Q3 | 77.83 Billion KRW | 14.28% |
| 2011 Q2 | 68.1 Billion KRW | 6.31% |
| 2011 Q1 | 64.06 Billion KRW | 52.08% |
| 2010 Q1 | 53.99 Billion KRW | 14.44% |
| 2010 Q3 | 41.08 Billion KRW | -26.21% |
| 2010 Q4 | 42.12 Billion KRW | 2.54% |
| 2010 FY | 42.12 Billion KRW | -10.72% |
| 2010 Q2 | 55.67 Billion KRW | 3.12% |
| 2009 Q4 | 47.18 Billion KRW | 10.68% |
| 2009 FY | 47.18 Billion KRW | 3.25% |
| 2009 Q3 | 42.63 Billion KRW | -11.29% |
| 2009 Q2 | 48.05 Billion KRW | -7.37% |
| 2009 Q1 | 51.87 Billion KRW | 13.52% |
| 2008 Q1 | 47.24 Billion KRW | 7.57% |
| 2008 Q2 | 48.44 Billion KRW | 2.54% |
| 2008 Q3 | 43.84 Billion KRW | -9.51% |
| 2008 Q4 | 45.69 Billion KRW | 4.24% |
| 2008 FY | 45.69 Billion KRW | 4.04% |
| 2007 Q2 | 46.69 Billion KRW | -5.52% |
| 2007 FY | 43.92 Billion KRW | 0.0% |
| 2007 Q1 | 49.42 Billion KRW | 0.0% |
| 2007 Q4 | 43.92 Billion KRW | -7.2% |
| 2007 Q3 | 47.33 Billion KRW | 1.36% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -119.324% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 81.635% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 75.85% |
| HANDOK Inc. | 449.7 Billion KRW | 62.028% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -99.323% |
| Yuhan Corporation | 712.33 Billion KRW | 76.028% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 72.977% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -974.339% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 79.954% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -219.008% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 17.056% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -127.163% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -15.539% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -142.553% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -119.324% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -368.656% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 32.009% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 22.63% |
| JW Holdings Corporation | 827.51 Billion KRW | 79.365% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 60.924% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 70.899% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 55.015% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -115.331% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -144.057% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 29.686% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 48.3% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -119.324% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 65.152% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 80.099% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 55.015% |
| Yuhan Corporation | 712.33 Billion KRW | 76.028% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 64.262% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -24.671% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 66.95% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 55.015% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -10.499% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -89.807% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 29.94% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -8.312% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -296.941% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -115.331% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 73.003% |
| Boryung Corporation | 373.1 Billion KRW | 54.233% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 17.981% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 17.056% |
| JW Lifescience Corporation | 96.44 Billion KRW | -77.058% |